Assessment of Quality of Life in Turkish Multiple Myeloma Patients by Using EORTC-QLQ-C30

Amaç: Multipl miyelomlu (MM) hastalarda hastalığa ve farklı tedavi modalitelerine bağlı gelişen depresyon, anksiyete ve hayat kalitesindeki değişiklikleri değerlendirdik; ve bu bozukluklarla kişisel ve demografik özellikler, hastalığın tipi ve evresi arasındaki ilişkiyi araştırdık. Materyal ve Metot: Merkezimizde takip edilen 50 MM hastası alındı. Bütün hastalar EORTC-QLQC30u, miyelom modülünü (EORTC QLQ-MY20), Genel Sağlık Sorgulamasını (GSS) ve Hastane Anksi-yete ve Depresyon Skalasını (HADS) cevapladılar. Bulgular: øyi ve kötü ECOG performans skalası olan hastalar arasında EORTC-QLQ-C30un fonksiyonel skalası (p

(Türk multipl miyelomlu hastalarda EORTC-QLQ-C30 kullanılarak hayat kalitesinin değerlendirilmesi)

Background: We evaluated depression, anxiety, and changes in quality of life (QoL) due to disease itself and its various treatment modalities in multiple myeloma (MM) patients; and determined the association between these disorders and features like personal and demographic characteristics, type and stage of disease. Materials and Methods: Fifty MM patients followed up at our center were included. All patients answered EORTC-QLQ-C30, and its myeloma module (EORTC QLQMY20), General Health Questionnaire (GHQ), and Hospital Anxiety and Depression Scale (HADS). Results: Patients with ECOG good or poor performance status differed significantly regarding EORTC-QLQ-C30 functional scale (p<0.005), symptom scale (p<0.01), global QoL (p<0.001), and EORTC-QLQ-MY20 scores (p<0.001). Patients with or without depression differed significantly in EORTC-QLQ-C30 scores (p<0.05), global QoL scores (p<0.001), and EORTC-QLQ-MY20 scores (p<0.05). Depression was seen to be an independent factor associated with global QoL. Conclusions: Performance status, anxiety and depresssion were observed to influence performance status in our MM patients. Factors which have the most negative impact on QoL are depression and side effects related to MM treatment.

PDF

___

1. Blade J, Cibeira MT, Fernandez de Larrea C, Rosiñol L. Multiple myeloma. Ann Oncol 2010; 21 Suppl 7:vii313-6.
2. Tricot G, Barlogie B, Van Rhee F. Treatment advances in multiple myeloma. Br J Haematol 2004;125:24-30.
3. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860-73.
4. Gulbrandsen N, Hjermstad MJ, Wisloff F. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 2004;72:172-80.
5. Holzner B, Kemmler G, Kopp M, et al. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 year. Eur J Haematol 2004;72:381-9.
6. Andrykowski MA, Greiner CB, Altmaier EM, et al. Quality of life following bone marrow transplantation: findings from a multicentre study. Br J Cancer 1995;71:1322-9.
7. Stark D, Kiely M, Smith A, Velikova G, House A, Selby P. Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 2002;20:3137-48.
8. Wisloff F, Eika S, Hippe E, et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1996;92:604-13.
9. Wisloff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol 1997;97:29-37.
10. Sprangers MA, Cull A, Bjordal K, Groenvold M, Aaronson NK. The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life. Qual Life Res 1993;2:287-95.
11. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders. Br J Haematol 2003;121:749-57.
12. Oken MM, Creech RH, Tormey DC, et al. Toxicity And Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
13. Taylor AE, Olver IN, Sivanthan T, Chi M, Purnell C. Observer error in grading performance status in cancer patients. Support Care Cancer 1999;7:332-5.
14. Zigmond AS, Snaith PR. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
15. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-oflife instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
16. Guzelant A, Göksel T, Özkök S, Tasbakan S, Aysan T, Bottomley A. The European Organization for Research and Treatment of Cancer QLQC30: An examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30. Eur J Cancer Care (Engl) 2004;13:135-44.
17. Stead ML, Brown JM, Velikova G, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol 1999;104:605-11.
18. Cocks K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007;43:1670-8.
19. Pamuk GE, Harmandar F, Ermantas N, et al. EORTC QLQ-C30 assessment in Turkish patients with hematological malignancies: association with anxiety and depression. Ann Hematol 2008;87:305-10.
20. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual (2001). 3rd edition. Brussels:EORTC, 1-24.
21. Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res 1997;6:103-8.
22. Cankurtaran ES, Özalp E, Soygur H, Ozer S, Akbiyik DI, Bottomley A. Understanding the reliability and validity of the EORTC QLQ-C30 in Turkish cancer patients. Eur J Cancer Care (Engl) 2008;17:98-10.